Pfizer looks past COVID with $43 billion deal for cancer drug innovator Seagen By Reuters
Pfizer has struck a $43bn deal for cancer therapy specialist Seagen as the company prepares to contend with a steep drop in COVID-19 product sales and fierce competition for some ...